SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
TRACON Pharmaceuticals, Inc. (TCON) , 前瞻盈利收益率 185.19%.
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
- 前瞻市盈率 0.5
SharesGrow 综合评分： 31/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✗
健康
0/100
Debt-to-Equity & liquidity
→ Health
估值概览 — TCON
估值倍数
P/E (TTM)0.0
前瞻 P/E0.5
PEG 比率N/A
前瞻 PEG0.00
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-2.19
前瞻 EPS（预估）$0.06
每股账面价值$0.00
每股营收$7.36
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield185.19%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2014 |
$-113.70 |
$3.6M |
$-6.81M |
-189.2% |
| 2015 |
$-439.20 |
$7.9M |
$-24.41M |
-308.8% |
| 2016 |
$-426.06 |
$3.45M |
$-27.01M |
-783.1% |
| 2017 |
$-227.33 |
$8.76M |
$-19.1M |
-218.2% |
| 2018 |
$-259.47 |
$3M |
$-34.96M |
-1165.3% |
| 2019 |
$-149.35 |
$0.00 |
$-22.66M |
- |
| 2020 |
$-38.57 |
$0.00 |
$-17.33M |
- |
| 2021 |
$-33.30 |
$346K |
$-28.73M |
-8302.3% |
| 2022 |
$-28.02 |
$0.00 |
$-29.31M |
- |
| 2023 |
$-2.19 |
$12.05M |
$-3.59M |
-29.8% |
